

# PRELIMINARY PROGRAM



**40<sup>TH</sup>**  
**VICENZA**  
**COURSE**

**on AKI & CRRT**  
special edition

**June 14-16, 2022**

Vicenza Convention Centre



@vicenzacourse

**ROOM A: AKI & SEPSIS**

Joint session University of Melbourne/IRRIV

Chairs: *R. Bellomo* — *S. De Rosa*9.00 AKI in sepsis: mechanisms, phenotype and biotype *E. See*9.20 Sepsis and AKI: where are we? *J.L. Vincent*9.40 Role of micovesicles *V. Cantaluppi*

9.50 Audience interaction and meet the expert interview

**ROOM B: AKI: NEW INSIGHTS**Chairs: *J. Prowle* — *M. Nadim*9.00 Snapshot on AKI worldwide *R.Mehta*9.20 AKI Risk : susceptibility, exposures and mitigators *K.D. Liu*9.40 Biomarkers derived AKI definition *J. Kellum*

9.50 Audience interaction and meet the expert interview

**ROOM C: BASICS of CRRT**

Joint session Purdue University/IRRIV

Chairs: *A. Brendolan* — *V. Narsimhan*9.00 Mechanisms of Transport in CRRT *W. Clark*9.25 CRRT Membrane structure and function *C. Ronco*

9.50 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

**ROOM A: BIOMARKERS**Chairs: *M. Ostermann* — *T. Reis*10.40 Can we use biomarkers to guide AKI management? *A. Zarbock*11.00 Can we use biomarkers to guide CRRT ? *M. Meersch*11.20 Biomarkers of kidney function in AKI: where do we stand? *C. Nussbag*

11.30 Audience interaction and meet the expert interview

**ROOM B: RECOVERY FROM AKI**Chairs: *N. Pannu* — *M. Okusa*10.40 Clinical patterns of recovery from AKI *L. Forni*11.05 Pathophysiological patterns of recovery from AKI *P. Romagnani*

11.30 Audience interaction and meet the expert interview

**ROOM C: BASICS OF ANTICOAGULATION**

Joint session SITI/IRRIV

Chairs: *A. Tolwani* — *P. Navalesi*10.40 Principles of anticoagulation *G. Villa*11.00 Heparin-based anticoagulation *S. Samoni*11.20 Citrate-based anticoagulation *S. Romagnoli*

11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

**ROOM 1** 12.30 Industry-Sponsored Activity**ROOM 2** 13.15 Industry-Sponsored Activity**PLENARY ROOM** Chairs: *R. Mehta* — *K.D. Liu***AKI&SEPSIS (state of the art)**14.00 AKI in sepsis: mechanisms, phenotype and biotype *R. Bellomo*14.10 Sepsis and AKI: where are we? *S. De Rosa*

14.20 Discussion

**AKI worldwide**14.30 Snapshot on AKI worldwide *J. Prowle*14.40 AKI Risk : susceptibility, exposures and mitigators *M. Nadim*

14.50 Discussion

**BASICS OF CRRT**15.00 Mechanisms of Transport in CRRT *V. Narsimhan*15.10 CRRT Membrane structure and function *A. Brendolan*

15.20 Discussion

**BIOMARKERS**15.30 Can we use biomarkers to guide AKI management? *M. Ostermann*15.40 Can we use biomarkers to manage CRRT? *L. Forni*

15.50 Discussion

**RECOVERY FROM AKI**16.00 Clinical patterns of recovery from AKI *N. Pannu*16.10 Pathophysiological patterns of recovery from AKI *M. Okusa*

16.20 Discussion

**BASICS OF ANTICOAGULATION**16.30 Principles and theory of anticoagulation *A. Tolwani*16.40 Heparin and citrate based anticoagulation in practice *G. Villa*

16.50 Discussion

**ROOM 1** 17.00 Industry-Sponsored Activity**ROOM 2** 17.30 Industry-Sponsored Activity

**ROOM A: PERSISTENT AKI**

Joint session UPMC/IRRIV

Chairs: *R. Murugan – S. Samoni*

- 9.00 Persistent AKI, a clinical and mechanistic fork in ICU patients *H. Gomez*  
 9.20 Persistent Kidney Dysfunction in Pediatric solid Organ Transplant *D. Fuhrman*  
 9.40 Persistent AKI: Precision medicine project *R. Murugan*  
 10.00 Audience interaction and meet the expert interview

**ROOM B: ADSORPTION, A NEW FRONTIER**Chairs: *G. Ankawi – R. Ratanarat*

- 9.00 Rationale for the use of adsorption in critical care medicine *R. Bellomo*  
 9.20 Hemoperfusion: mechanisms, indications and clinical application *C. Ronco*  
 9.40 Techniques of adsorption: from direct hemoperfusion to DPMAS *J. Prowle*  
 10.00 Audience interaction and meet the expert interview

**ROOM C: DIGITAL HEALTH and AKI**

Joint session Mayo Clinic/IRRIV

Chairs: *S. Bagshaw – D. Soranno*

- 9.00 Summary of ADQI consensus on digital health in AKI/CRRT *K. Kashani*  
 9.20 Using digital health of post-AKI management *A. Kattah*  
 9.40 Barriers in implementation and maintenance of digital health for AKI *D. Soranno*  
 10.00 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

**ROOM A: BLOOD PURIFICATION IN SEPSIS**Chairs: *C. Ronco – M. Proglia*

- 10.40 Why using EBP in sepsis? *J. Kellum*  
 11.00 Pathogen removal sepsis *L. Chawla*  
 11.20 Cytokine removal in sepsis *T. Rimmelé*  
 11.40 Audience interaction and meet the expert interview

**ROOM B: AKI&CRRT in SEPSIS and Covid-19**Chairs: *F. Husain-Syed – A. Nishio Lucar*

- 10.40 AKI epi in Covid 19 patients: short and long-term consequences *N. Srisawat*  
 11.00 Report from ADQI consensus on prevention and management *M. Nadim*  
 11.20 Clinical experience with PSP *G. Castellano*  
 11.40 Audience interaction and meet the expert interview

**ROOM C: AKI&CRRT in PEDIATRICS**

Joint session CCHMC/IRRIV

Chairs: *S. Goldstein - M. Zanella*

- 10.40 Worldwide and US experience with neonatal CRRT machine *C. Slagle*  
 11.00 AKI transition to CKD in pediatrics *D. Cooper*  
 11.20 Hemoperfusion in pediatric patients *G. Bottari*  
 11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

**ROOM 1** 12.30 Industry-Sponsored Activity**ROOM 2** 13.15 Industry-Sponsored Activity**PLENARY ROOM** Chairs: *H. Gomez – D. Fuhrman***PERSISTENT AKI**

- 14.00 Persistent AKI, a clinical and mechanistic fork in ICU patients  
 14.10 Persistent AKI: The precision medicine project  
 14.20 Discussion

*S. Samoni  
R. Murugan***ADSORPTION, A NEW FRONTIER IN BLOOD PURIFICATION**

- 14.30 Rationale for the use of adsorption in critical care medicine  
 14.50 Hemoperfusion: mechanisms, indications and applications  
 15.00 Discussion

*G. Ankawi  
T. Rimmelé***DIGITAL HEALTH AND AKI**

- 15.10 Using digital health of post-AKI management  
 15.20 Barriers in implementation and maintenance of digital health for AKI  
 15.20 Discussion

*S. Bagshaw  
D. Soranno***EXTRACORPOREAL BLOOD PURIFICATION IN SEPSIS**

- 15.30 Membrane-based techniques in sepsis  
 15.40 Sorbent-based techniques in sepsis  
 15.50 Sequential extracorporeal therapy in sepsis  
 16.00 Discussion

*G. Villa  
C. Ronco  
S. De Rosa***AKI AND CRRT IN COVID 19: FROM FIRST WAVE TO OMICRON**

- 16.10 AKI in Covid-19: short and long term consequences  
 16.20 Report from ADQI consensus on AKI in Covid-19  
 16.30 Discussion

*F. Husain-Syed  
T. Reis***AKI and CRRT in PEDIATRICS**

- 16.40 AKI in pediatrics and transition to CKD  
 16.50 CRRT in pediatrics: an update  
 17.00 Neonatal CRRT technology and outcomes  
 17.10 Discussion

*S. Goldstein  
Z. Ricci  
C. Slagle***ROOM 1** 17.20 Industry-Sponsored Activity**ROOM 2** 17.50 Industry-Sponsored Activity

**ROOM A: AKI BIOLOGY**

Joint session UVA/IRRIV

Chairs: *M. Okusa – V. Cantaluppi*

- 9.00 Transplant AKI in times of COVID-19  
*A. Nishio Lucar*
- 9.20 Cell Death and Clearance during AKI  
*S. Morioka*
- 9.40 Pulsed Ultrasound to treat Inflammation and AKI  
*F. Husain-Syed*
- 10.00 Audience interaction and meet the expert interview

**ROOM B: BIOMARKERS IN CLINICAL PRACTICE**

UCD Dublin-CHUM Montreal/IRRIV

Chairs: *A. Brendolan—P. Murray*

- 9.00 Biomarkers to differentiate functional versus intrinsic AKI  
*S. Duff*
- 9.20 Implementation of AKI biomarkers in clinical practice  
*J-M. Côté*
- 9.40 Biomarkers to predict AKI progression to CKD versus recovery  
*L. Redahan*
- 10.00 Audience interaction and meet the expert interview

**ROOM C: THERAPEUTIC APHERESIS**Chairs: *M. Nadim—D. Fuhrman*

- 9.00 Emerging Trends in Extracorporeal Therapies (Apheresis) for AKI in Sepsis  
*R. Balogun*
- 9.20 Immunoabsorption as a treatment options for neurological autoimmune disease  
*S.C. Boedecker-Lips*
- 9.40 Immunoapheresis in ABO incompatible Transplant  
*TBD*
- 10.00 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

**ROOM A: EXTRACORPOREAL ORGAN SUPPORT**Chairs: *T. Rimmelé—M. Cannone*

- 10.40 Impact of Hemoperfusion on microcirculation and sepsis  
*C. Ince*
- 11.00 Extracorporeal Lung Support  
*A. Combes*
- 11.20 Extracorporeal Liver support  
*M. Nadim*
- 11.40 Audience interaction and meet the expert interview

**ROOM B: QUALITY MEASURES in AKI&CRRT**

Joint session University of Alberta/IRRIV

Chairs: *S. Bagshaw – D. Soranno*

- 10.40 Digital Health Transformation and Implementation in AKI  
*N. Pannu*
- 11.00 Quality Indicator and Best Practice Implementation in Acute RRT  
*O. Rewa*
- 11.20 STARRT-AKI secondary studies and clinical Implications  
*S. Bagshaw*
- 11.40 Audience interaction and meet the expert interview

**ROOM C: FLUID OVERLOAD and MANAGEMENT**Chairs: *N. Aspromonte – A. Kattah*

- 10.40 Fluid overload: when diuretics fail  
*M. Ostermann*
- 11.00 Current practice of extracorporeal fluid management  
*A. Kazory*
- 11.20 Rationale for a new compact and portable ultrafiltration device  
*C. Ronco*
- 11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

**ROOM 1** 12.30 Industry-Sponsored Activity**ROOM 2** 13.15 Industry-Sponsored Activity**PLENARY ROOM**Chairs: *M. Ostermann – A. Zarbock***AKI BIOLOGY**

- 14.00 Transplant AKI in times of COVID-19
- 14.10 Cell Death and Clearance during AKI
- 14.20 Pulsed Ultrasound to treat Inflammation and AKI
- 14.30 Discussion

*A. Nishio Lucar*  
*S. Morioka*  
*F. Husain-Syed*

**BIOMARKERS IN CLINICAL PRACTICE**

- 14.40 Biomarkers of Drug-induced Acute Kidney Injury
- 14.50 Biomarkers to differentiate functional versus intrinsic AKI
- 15.00 Implementation of AKI biomarkers in clinical practice
- 15.10 Discussion

*P. Murray*  
*S. Duff*  
*J-M. Côté*

**APHERESIS AND EXTRACORPOREAL ORGAN SUPPORT**

- 15.20 Emerging Trends in Extracorporeal Therapies (Apheresis) for AKI in Sepsis
- 15.30 Immunoabsorption as a treatment options for neurological autoimmune disease
- 15.40 Organ ex vivo perfusion for transplantation & marginal organ recovery
- 15.50 Discussion

*R. Balogun*  
*S.C. Boedecker-Lips*  
*A. Bertacco*

**ECOS**

- 16.00 Circulatory effects of hemoperfusion
- 16.10 Extracorporeal Lung support
- 16.20 Extracorporeal Liver support
- 16.30 Discussion

*C. Ince*  
*A. Combes*  
*R. Ratanarat*

**QUALITY MEASURES in AKI & CRRT**

- 16.40 Digital Health Transformation and Implementation in AKI
- 16.50 Quality Indicator and Best Practice Implementation in Acute RRT
- 17.00 STARRT-AKI secondary studies and clinical implications
- 17.10 Discussion

*N. Pannu*  
*O. Rewa*  
*S. Bagshaw*

**FLUID OVERLOAD MANAGEMENT**

- 17.20 Fluid overload: when diuretics fail
- 17.30 Current practice of extracorporeal fluid management
- 17.40 Discussion

*N. Aspromonte*  
*A. Kattah*

**ROOM 1** 17.50 Industry-Sponsored Activity**ROOM 2** 18.20 Industry-Sponsored Activity